Evidence map›Paper›PMID 36653082›Full record

ArticleMethods in cell biology2023

Standardized protocol for the evaluation of chimeric antigen receptor (CAR)-modified cell immunological synapse quality using the glass-supported planar lipid bilayer.

Jong Hyun Cho, Wei-Chung Tsao, Alireza Naghizadeh, Dongfang Liu

Open access · greenAbstract read
In one paragraph

Article in Methods in cell biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jong Hyun ChoDepartment of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School, Newark, NJ, United States; Center for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, United States.
Wei-Chung TsaoDepartment of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School, Newark, NJ, United States; Center for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, United States.
Alireza NaghizadehDepartment of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School, Newark, NJ, United States; Center for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, United States.
Dongfang LiuDepartment of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School, Newark, NJ, United States; Center for Immunity and Inflammation, New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ, United States. Electronic address: dongfang.liu@rutgers.edu.
Rutgers New Jersey Medical SchoolRutgers, The State University of New Jersey · US

Funding

The adaptor protein Crk in immune responsesR01AI130197 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Dongfang Liu · 2018 to 2026
$4.2M
Leica TCS SP8 STED 3x super resolution microscope for the RBHS Newark campusS10OD025182 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI LIU, DONGFANG · 2020 to 2020
$961k
The adaptor protein Crk in immune responsesR56AI130197 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI LIU, DONGFANG · 2017 to 2023
$874k
Bispecific cytotoxic lymphocytes in HIV-related lymphomaR21HL125018 · NHLBI · RBHS-NEW JERSEY MEDICAL SCHOOL · PI LIU, DONGFANG · 2015 to 2016
$449k
HIV-1-Specific CTL Exhaustion at Immune SynapseR21AI124769 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI LIU, DONGFANG · 2016 to 2017
$446k
Targeting of Master Signaling Molecule to Restore Functions of Exhausted HIV-specific CTLsR21AI129594 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI LIU, DONGFANG · 2017 to 2018
$438k
CD147-CAR-NK Cells for Hepatocellular Carcinoma TreatmentR21CA267368 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI LIU, DONGFANG · 2022 to 2023
$391k
NCI NIH HHS R21 CA267368NHLBI NIH HHS R21 HL125018NIAID NIH HHS R01 AI130197NIAID NIH HHS R21 AI124769NIAID NIH HHS R21 AI129594NIAID NIH HHS R56 AI130197NIH HHS S10 OD025182
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-modified cell therapy is an effective therapy that harnesses the power of the human immune system by re-engineering immune cells that specifically kill tumor cells with tumor antigen specificity. Key to the effective elimination of tumor cells is the establishment of the immunological synapse (IS) between CAR-modified immune cells and their susceptible tumors. For functional activity, CAR-modified cells must form an effective IS to kill tumor cells specifically. The formation of the CAR-specific IS requires the coordination of many cellular processes including reorganization of the cytoskeletal structure, polarization of lytic granules, accumulation of tumor antigen, and phosphorylation of key signaling molecules within the IS. Visualization and assessment of the CAR IS quality can reveal much about the molecular mechanisms that underlie the efficacy of various CAR-modified immune cells. This chapter provides a standardized method of assessing the IS quality by quantifying the tumor antigen (defining the CAR IS formation), cytoskeleton (key component of CAR IS structure), and various molecules of interest involved in the IS formation (key molecular mechanism signatures of CAR IS function) using immunofluorescence on the glass-supported planar lipid bilayer, with a focus on tumor antigen only in this study. We provide specific insights and helpful tips for reagent and sample preparation, assay design, and machine learning (ML)-based data analysis. The protocol described in this chapter will provide a valuable tool to visualize and assess the IS quality of various CAR-modified immune cells.

Indexed as

NeoplasmsReceptors, Chimeric AntigenAntigens, NeoplasmHumansImmunological SynapsesLipid BilayersReceptors, Antigen, T-CellAntigens, NeoplasmLipid BilayersReceptors, Antigen, T-CellReceptors, Chimeric AntigenChimeric antigen receptorImmunological synapseLipid bilayers

Identifiers

PMID36653082
PMCPMC10768727
OpenAlexW4312887474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.